Silver Creek Pharmaceuticals
June 16, 2025
Company Presentation
Brain Health
Silver Creek Pharmaceuticals combines the natural and validated therapeutic power of growth factors with molecular engineering to develop differentiated medicines for critical patient needs. We aim to become the leader in growth factor-based therapeutic development.
Our lead asset, scp776, is a first-in-class engineered insulin-like growth factor (IGF-1) that targets apoptotic cells and protects from cell death. Scp776 selectively accumulates in injured tissues and drives pro-survival signaling.
Our Phase 2a proof-of-concept study of scp776 in acute ischemic stroke will read out in mid-2025. This study aims to demonstrate scp776's ability to induce apoptosis escape and provide neuroprotective benefits in humans.
Company HQ City:
South San Francisco
Company HQ State:
CA
Company HQ Country:
United States
Year Founded:
2010
Lead Product in Development:
scp776
CEO
Karim Dabbagh, PhD (President & CEO)
Development Phase of Lead Product
Phase II
Number of Unlicensed Products Looking for Licensing
1
When you expect your next catalyst update?
Phase 2a data card for scp776 in acute ischemic stroke
What is your next catalyst (value inflection) update?
October 2025
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}